A Study to Determine the Effectiveness of Endoscopic Full-Thickness Plication for the Treatment of GERD
Primary Purpose
Gastroesophageal Reflux Disease (GERD)
Status
Terminated
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
NDO Full-thickness Plicator
Sham Control
Sponsored by
About this trial
This is an interventional treatment trial for Gastroesophageal Reflux Disease (GERD) focused on measuring GERD, Sham, Randomized Controlled Study, Endoscopic Full-thickness Plication, Plicator
Eligibility Criteria
Patients 18 years or older with a history of heartburn or regurgitation symptoms requiring daily PPI therapy were recruited.
Inclusion Criteria:
- GERD-HRQL score ≥ 15 while off PPI therapy, and at least 6 points higher than on-PPI score
- Pathologic esophageal acid exposure, defined as pH<4.0 ≥ 4.5% of a 24- or 48-hour monitoring period or a DeMeester score > 14.7
- Lower esophageal resting pressure of at least 5mmHg; and
- Suitability for surgery (American Society of Anesthesiologists Physical Status Classification I or II).
Exclusion Criteria:
- Significant esophageal dysmotility as determined by manometry
- Esophagitis grade III or IV (Savary-Miller)
- Barrett's epithelium
- Hiatus hernia > 2cm
- Persistent dysphagia, weight loss, esophageal bleeding, vomiting, gas or bloating
- Esophageal or gastric varices
- Previous endoscopic or surgical anti-reflux procedure
- Other esophageal or gastric surgery
- Chronic use of anticoagulant or platelet anti-aggregation therapy (other than for cardiac prophylaxis); and
- Pregnancy.
Sites / Locations
- University of California at Irvine Medical Center
- Tri Valley Gastroenterology
- University of Colorado Health Science Center
- Beth Israel Deaconess Medical Center
- Creighton University Medical Center
- Seacoast Gastroenterology
- Dartmouth Hitchcock Medical Center
- Lenox Hill Hospital
- Columbia University Medical Center
- Nashville Medical Research and the Maria Nathanson Center of Excellence
- Vanderbilt University Medical Center
- Virginia Mason Medical Center
- Digestive Health Specialists
- Erasme Hospital
- Klinikum Ludwigsburg, University of Heidelburg
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Sham Comparator
Arm Label
1
2
Arm Description
NDO Endoscopic Full-thickness Plicator procedure
Sham control procedure
Outcomes
Primary Outcome Measures
>/=50% improvement in GERD-Health Related Quality of Life Score
Secondary Outcome Measures
GERD medication use
Esophageal acid exposure
Heartburn score as measure by visual analog scale
Quality of Life as measure by SF-36
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00575822
Brief Title
A Study to Determine the Effectiveness of Endoscopic Full-Thickness Plication for the Treatment of GERD
Official Title
Endoscopic Full-Thickness Plication for the Treatment of Gastroesophageal Reflux Disease: A Randomized, Sham-Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
May 2008
Overall Recruitment Status
Terminated
Why Stopped
Sponsoring company ceased business operations.
Study Start Date
January 2005 (undefined)
Primary Completion Date
March 2008 (Actual)
Study Completion Date
March 2008 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
NDO Surgical, Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of this study was to determine the effectiveness of endoscopic full-thickness plication (Plicator; NDO Surgical, Inc., Mansfield, MA) for the treatment of GERD in comparison to a sham procedure.
Patients with symptomatic GERD requiring maintenance proton pump inhibitor therapy were entered into a randomized, single-blind, prospective, multicenter trial. Seventy-eight patients were randomly assigned to undergo endoscopic full-thickness restructuring of the gastric cardia with transmural suture. Eighty-one patients underwent a sham procedure. Group assignments were revealed following the 3-month evaluation. The primary endpoint was ≥ 50% improvement in GERD-HRQL score. Secondary endpoints included medication use and esophageal acid exposure.
Patients achieving ≥ 50% improvement in GERD-HRQL score at 3-months versus baseline off-meds were considered responsive to their assigned procedure. Patients who failed to reach this level of improvement at 3-months were considered non-responders. Analysis of these dichotomized variables (responder/non-responder) was done using Fisher's exact test comparing the proportion of responders between the active and sham groups. Intent-to-treat analysis was also performed. The null hypothesis was that the proportion of responders was the same in both the active and sham groups. Testing was done at the 5% level of significance (alpha=0.05).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastroesophageal Reflux Disease (GERD)
Keywords
GERD, Sham, Randomized Controlled Study, Endoscopic Full-thickness Plication, Plicator
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
159 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Active Comparator
Arm Description
NDO Endoscopic Full-thickness Plicator procedure
Arm Title
2
Arm Type
Sham Comparator
Arm Description
Sham control procedure
Intervention Type
Device
Intervention Name(s)
NDO Full-thickness Plicator
Other Intervention Name(s)
Active Plicator procedure
Intervention Description
A low-profile (≤6mm) gastroscope was advanced and an EGD followed by Savary wire placement was performed. The gastroscope was then removed and the Plicator was advanced directly over the wire and into the stomach. The gastroscope was re-introduced through the Plicator, and the Plicator was retroflexed under direct endoscopic visualization to the anterior gastric cardia, approximately 1cm below the gastroesophageal (GE) junction. The Plicator arms were opened and the endoscopic tissue retractor was advanced deeply into the gastric cardia. The gastric wall was then retracted into the open arms of the Plicator. The arms were closed and a single, transmural pledgeted suture was deployed. The Plicator and gastroscope were then removed and the gastroscope re-inserted to evaluate the post-plication GE junction.
Intervention Type
Device
Intervention Name(s)
Sham Control
Other Intervention Name(s)
Sham control procedure
Intervention Description
The sham procedure was identical to the treatment procedure through the positioning of the retroflexed Plicator 1cm below the GE junction. The Plicator instrument remained in this position for 15 minutes, based on average procedure times established in previous studies. During the sham procedure, physician investigators were required to talk through the procedure steps to maintain the patient blind.
Primary Outcome Measure Information:
Title
>/=50% improvement in GERD-Health Related Quality of Life Score
Time Frame
3-months post-procedure
Secondary Outcome Measure Information:
Title
GERD medication use
Time Frame
3-months post-procedure
Title
Esophageal acid exposure
Time Frame
3-months post-procedure
Title
Heartburn score as measure by visual analog scale
Time Frame
3-months post-procedure
Title
Quality of Life as measure by SF-36
Time Frame
3-months post-procedure
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Patients 18 years or older with a history of heartburn or regurgitation symptoms requiring daily PPI therapy were recruited.
Inclusion Criteria:
GERD-HRQL score ≥ 15 while off PPI therapy, and at least 6 points higher than on-PPI score
Pathologic esophageal acid exposure, defined as pH<4.0 ≥ 4.5% of a 24- or 48-hour monitoring period or a DeMeester score > 14.7
Lower esophageal resting pressure of at least 5mmHg; and
Suitability for surgery (American Society of Anesthesiologists Physical Status Classification I or II).
Exclusion Criteria:
Significant esophageal dysmotility as determined by manometry
Esophagitis grade III or IV (Savary-Miller)
Barrett's epithelium
Hiatus hernia > 2cm
Persistent dysphagia, weight loss, esophageal bleeding, vomiting, gas or bloating
Esophageal or gastric varices
Previous endoscopic or surgical anti-reflux procedure
Other esophageal or gastric surgery
Chronic use of anticoagulant or platelet anti-aggregation therapy (other than for cardiac prophylaxis); and
Pregnancy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Richard Rothstein, MD
Organizational Affiliation
Dartmouth-Hitchcock Medical Center, Lebanon, NH
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Charles Filipi, MD
Organizational Affiliation
Creighton University Medical Center, Omaha, NE
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Karel Caca, MD
Organizational Affiliation
Klinikum Ludwigsburg, University of Heidelburg, Heidelburg, Germany
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ronald Pruitt, MD
Organizational Affiliation
Nashville Medical Research and the Maria Nathanson Center of Excellence, Nashville, TN
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Klaus Mergener, MD
Organizational Affiliation
Digestive Health Specialists, Tacoma, WA
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Alfonso Torquati, MD
Organizational Affiliation
Vanderbilt University Medical Center, Nashville, TN
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Gregory Haber, MD
Organizational Affiliation
Lenox Hill Hospital, New York, NY
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Yang Chen, MD
Organizational Affiliation
University of Colorado Health Science Center, Denver, CO
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Kenneth Chang, MD
Organizational Affiliation
University of California at Irvine Medical Center, Orange, CA
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
David Wong, MD
Organizational Affiliation
Tri Valley Gastroenterology, San Ramon, CA
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jacques Deviere, MD
Organizational Affiliation
Erasme Hospital, Brussels, Belgium
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Douglas Pleskow, MD
Organizational Affiliation
Beth Israel Deaconess Medical Center, Boston MA
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Charles Lightdale, MD
Organizational Affiliation
Columbia University Medical Center, New York, NY
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Alain Ades, MD
Organizational Affiliation
Seacoast Gastroenterology, Exeter, NH
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Richard Kozarek, MD
Organizational Affiliation
Virginia Mason Medical Center, Seattle, WA
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California at Irvine Medical Center
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Facility Name
Tri Valley Gastroenterology
City
San Ramon
State/Province
California
ZIP/Postal Code
94583
Country
United States
Facility Name
University of Colorado Health Science Center
City
Denver
State/Province
Colorado
ZIP/Postal Code
80010
Country
United States
Facility Name
Beth Israel Deaconess Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Facility Name
Creighton University Medical Center
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68131
Country
United States
Facility Name
Seacoast Gastroenterology
City
Exeter
State/Province
New Hampshire
ZIP/Postal Code
03833
Country
United States
Facility Name
Dartmouth Hitchcock Medical Center
City
Lebanon
State/Province
New Hampshire
ZIP/Postal Code
03756
Country
United States
Facility Name
Lenox Hill Hospital
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States
Facility Name
Columbia University Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Facility Name
Nashville Medical Research and the Maria Nathanson Center of Excellence
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37205
Country
United States
Facility Name
Vanderbilt University Medical Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37240
Country
United States
Facility Name
Virginia Mason Medical Center
City
Seattle
State/Province
Washington
ZIP/Postal Code
98101
Country
United States
Facility Name
Digestive Health Specialists
City
Tacoma
State/Province
Washington
ZIP/Postal Code
98405
Country
United States
Facility Name
Erasme Hospital
City
Brussels
Country
Belgium
Facility Name
Klinikum Ludwigsburg, University of Heidelburg
City
Heidelberg
ZIP/Postal Code
71640
Country
Germany
12. IPD Sharing Statement
Citations:
PubMed Identifier
16952539
Citation
Rothstein R, Filipi C, Caca K, Pruitt R, Mergener K, Torquati A, Haber G, Chen Y, Chang K, Wong D, Deviere J, Pleskow D, Lightdale C, Ades A, Kozarek R, Richards W, Lembo A. Endoscopic full-thickness plication for the treatment of gastroesophageal reflux disease: A randomized, sham-controlled trial. Gastroenterology. 2006 Sep;131(3):704-12. doi: 10.1053/j.gastro.2006.07.004.
Results Reference
result
Learn more about this trial
A Study to Determine the Effectiveness of Endoscopic Full-Thickness Plication for the Treatment of GERD
We'll reach out to this number within 24 hrs